Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2022-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2022年半年度报告（更正后）
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年半年度报告' which translates to '2022 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, financial indicators, and other substantive financial and operational information for the half-year period ending June 30, 2022. The length is about 15,000 characters, indicating a full report rather than a brief announcement. The content includes financial statements, management analysis, risk disclosures, and operational details typical of an Interim / Quarterly Report. There is no indication that this is an announcement of a report or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-25 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年半年度报告' which translates to '2022 Semi-Annual Report'. It contains detailed financial data, management discussion and analysis, company overview, business segments, financial indicators, and other substantive financial information for the half-year period ending June 30, 2022. The document length is about 15,000 characters, indicating a full report rather than a brief announcement. It includes actual financial statements and analysis, not just references or certifications. The presence of management discussion and analysis, financial data, and comprehensive business information confirms this is an Interim / Quarterly Report rather than an Annual Report or Earnings Release. Therefore, the appropriate classification is 'Interim / Quarterly Report' (IR). H1 2022
2022-08-25 Chinese
2022年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2022 年半年度财务报告" which translates to "2022 Half-Year Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity. The report explicitly states it is a half-year report and includes comprehensive financial data for the period ending June 30, 2022. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report or a certification letter. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-25 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is an independent director's opinion on specific matters related to the company's half-year period ending June 30, 2022. It discusses the use of funds by controlling shareholders and related parties, external guarantees, and a special report on the storage and use of raised funds for the half-year period. The document references regulatory guidelines and compliance but does not contain full financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report (IR). Instead, it is a standalone opinion or certification related to specific regulatory compliance and fund usage. Given the short length (1272 characters) and the nature of the content, it fits best as a Regulatory Filing (RNS) rather than a full financial report or audit report.
2022-08-25 Chinese
关于提前归还非公开发行部分暂时补充流动资金的募集资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the early repayment of temporarily supplemented funds from non-publicly issued raised funds. It discusses the use and repayment of raised funds, referencing previous board resolutions and public announcements. The content focuses on capital management and financing activities rather than financial results, management changes, or regulatory certifications. The document length is short (981 characters) and it is a formal announcement about financing activity, not a full financial report or audit. Therefore, it fits best under Capital/Financing Update (CAP).
2022-08-19 Chinese
关于控股股东股份解除质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the release of pledged shares by the controlling shareholders of the company. It details the number of shares released from pledge, the shareholders involved, and the status of pledged shares. It includes tables with shareholding and pledge information, explanations about the pledge status, and references to related documents. There is no financial statement, earnings data, or management discussion. The document is a regulatory announcement about share pledge status, not a financial report or management report. It fits the category of Regulatory Filings (RNS) as it is a compliance disclosure about share pledge changes by major shareholders.
2022-08-17 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.